Polynucleotides (PN): Science, Limits, and Hype
How polynucleotide and PDRN injections work, what clinical evidence supports, how Korea uses them, and where marketing exceeds the science.
Your Skin Looks Different, Not Damaged
You have started to notice something that is hard to name precisely. The skin is not wrinkled, exactly. It is not sagging. But it has lost a quality — a translucency, a resilience, a responsiveness to touch — that it had five years ago. Foundation sits on it rather than blending into it. The texture is finer in some areas, rougher in others. It is not a problem with a name. It is a shift in the baseline.
This is the presentation that brings many patients to ask about polynucleotides: not damage, but deterioration. Not a lesion, but a loss of biological quality that conventional treatments seem to work around rather than address.
Regenerative Is a Category, Not a Guarantee
The word "regenerative" is doing enormous work in aesthetic medicine right now, and much of that work is marketing rather than mechanism. To evaluate polynucleotides honestly, we need to separate what the molecules actually do from the aura that the category projects.
Polynucleotides are fragments of DNA — deoxyribonucleic acid polymers, typically 50 to 1,500 kilodaltons in molecular weight, derived from the sperm cells of salmon or trout. They are not stem cells. They are not growth factors. They are not exosomes. They are nucleic acid chains that, when introduced into tissue, activate specific biological pathways: primarily the adenosine A2A receptor, which triggers downstream effects on inflammation, angiogenesis, and fibroblast proliferation.
This is genuinely interesting biology. But "interesting biology" and "proven clinical therapy" are not the same thing, and the distance between them is where patients need the most honest guidance.
The critical conceptual reframe: polynucleotides are biologically active molecules with demonstrated cellular effects. Whether those cellular effects translate reliably into visible, lasting clinical improvement across the range of conditions they are marketed for — that is a different and more demanding question.
What the Science Shows — and Where It Stops
PN, PDRN, and Exosomes Are Not the Same Thing
The first source of confusion is categorical. Three distinct entities are routinely grouped under the "regenerative injection" umbrella, and the differences matter.
PDRN (polydeoxyribonucleotide) is the most studied. Molecular weight ranges from 50 to 1,500 kDa. The primary mechanism is A2A adenosine receptor activation, which reduces inflammation, promotes angiogenesis (new blood vessel formation), and stimulates fibroblast activity. PDRN has the strongest evidence base, particularly in wound healing.
PN (polynucleotide) is a broader category that includes longer-chain DNA fragments, often above 1,000 kDa. These longer chains may offer additional scaffolding effects — physically supporting extracellular matrix formation — beyond the receptor-mediated pathways of shorter PDRN fragments. The distinction is pharmacologically meaningful, even if marketing often ignores it.
Exosomes are an entirely different biological entity — lipid-membrane vesicles secreted by cells, carrying proteins, RNA, and signaling molecules. They share the "regenerative" label but operate through different mechanisms, have different evidence profiles, and face different regulatory questions. Conflating them with polynucleotides is like calling a vitamin and an antibiotic both "pills" — technically true, clinically misleading.
The implication: when a clinic offers "regenerative injections," the first question is which molecule, not which brand.
The Mechanism of Action Is Real but Specific
At the cellular level, PDRN and PN work through identifiable pathways. A2A receptor activation on fibroblasts increases collagen synthesis, upregulates vascular endothelial growth factor (VEGF) for angiogenesis, and modulates inflammatory cytokines. In tissue with compromised vascularity or chronic low-grade inflammation — such as aging dermis — these effects have a plausible basis for improving tissue quality.
In wound healing, this mechanism is well supported. Randomized controlled trials have demonstrated PDRN efficacy in diabetic foot ulcers, where angiogenesis and anti-inflammatory activity directly address the pathology. The evidence here is robust enough to inform clinical practice.
The translation to aesthetic medicine, however, involves a leap. Aging skin is not a wound. The biological environment of photoaged dermis in a healthy patient is different from a diabetic ulcer, and the magnitude of improvement achievable by A2A activation in otherwise healthy tissue is less established.
The implication: the mechanism is not fabricated — it is real biochemistry. But a real mechanism does not guarantee a clinically meaningful result in every context where it is applied.
What RCTs Actually Demonstrate in Aesthetics
Controlled studies in the aesthetic context show that PN/PDRN injections can improve skin hydration, as measured by corneometry. Some trials demonstrate improvement in skin elasticity measurements and fine line scores. Patient satisfaction scores tend to be positive, particularly for overall skin quality and texture.
What the controlled evidence does not robustly support — at least not yet — includes dramatic reversal of deep wrinkles, significant pore size reduction, meaningful improvement in deep scarring, or structural rejuvenation comparable to surgical or device-based interventions. These claims appear regularly in marketing materials and social media, but they are extrapolated from the mechanism or drawn from uncontrolled case series, not from head-to-head RCTs with standardized outcome measures.
This does not mean polynucleotides do not work. It means their demonstrated benefit is real but moderate, and the range of conditions for which they are marketed significantly exceeds the range for which controlled evidence exists.
Korea as the Global Center of PN/PDRN Practice
Korea's role in polynucleotide medicine is not incidental. Rejuran, one of the earliest and most widely known PDRN products, was developed by Pharma Research in Korea. Korean dermatologists and aesthetic physicians were among the first to integrate PDRN into routine clinical practice, accumulating years of real-world experience before the products gained significant international attention.
Products like Rejuran HB (for skin hydration), Rejuran S (for scarring), and Rejuran I (for periorbital use) represent a level of indication-specific product differentiation that reflects the maturity of the Korean market. Italian products — Nucleofill and Plinest — have entered the space with different polynucleotide formulations, creating a growing but still heterogeneous product landscape.
Korean dermatologists have developed nuanced protocols: intradermal injections at the papillary dermal level using a serial micro-deposit technique, typically three to five sessions spaced two to four weeks apart, followed by maintenance every one to three months. Many practitioners combine PN/PDRN injections with complementary modalities — laser toning, microneedling, radiofrequency devices — in structured combination protocols that address multiple aspects of skin quality simultaneously.
For international patients exploring these treatments, Korea offers both the deepest clinical experience and the widest product availability. Understanding the physician consultation process helps contextualize how these protocols are developed on an individual basis.
Where the Evidence Ends and the Uncertainty Begins
Several important limitations deserve explicit acknowledgment.
Standardization is lacking. PN products vary in molecular weight distribution, source species, purification method, concentration, and formulation. A 20 mg/mL PDRN product derived from salmon DNA with a mean molecular weight of 250 kDa is not the same as a 25 mg/mL PN product from trout with fragments averaging 1,200 kDa. Yet both are marketed as "polynucleotide injections." This heterogeneity makes it difficult to compare studies across products or to generalize results from one formulation to another.
Dose-response relationships are poorly characterized. How much polynucleotide, at what depth, at what interval, produces optimal results? Clinical protocols exist based on experience, but the dose-optimization studies that would anchor these protocols in evidence have not been performed for most aesthetic indications.
Long-term outcomes are uncertain. Most studies follow patients for three to twelve months. Whether the skin quality improvements from PN/PDRN are maintained beyond that window — or whether they require indefinite maintenance — is not well established. The biological plausibility argument (you are stimulating collagen and angiogenesis, which should produce lasting structural change) is reasonable but unconfirmed by long-term controlled data.
Regulatory landscapes vary dramatically. In Korea and parts of Europe, PN/PDRN products have established regulatory pathways. In other markets, including parts of the United States, the regulatory classification is less clear, and some products are used off-label or operate in gray areas. Patients traveling internationally for these treatments should understand that regulatory approval in one country does not guarantee the same status elsewhere.
Physicians disagree on the magnitude of benefit. Some dermatologists consider PN/PDRN a foundational element of skin quality management. Others view it as a modest adjunct — helpful in combination protocols but overstated as a standalone treatment. This disagreement is not resolved by existing evidence, and both positions can be held in good faith.
Thinking Clearly About a Promising but Incomplete Story
If you are considering polynucleotide treatment, the productive questions are not "does it work" or "is it worth it" in the abstract. The productive questions are specific.
What exactly is my skin quality concern? Is it hydration, texture, fine lines, elasticity, or something else? Is PN/PDRN the most evidence-supported intervention for that specific concern, or am I being offered it because it is novel and marketable?
Which specific product is being recommended, and what is its evidence base? Not the evidence for polynucleotides in general, but for this product, at this concentration, for this indication.
Is this being proposed as a standalone treatment or as part of a combination protocol? If standalone, what is the realistic expected improvement? If combination, which element is doing the most work?
What does the maintenance schedule look like, and what happens to the improvements if I stop?
A physician who can answer these questions with specificity — citing the evidence where it exists and acknowledging the limits where it does not — is a physician working from clinical reasoning. A physician who speaks in generalities about "regeneration" and "cellular renewal" without mechanistic specificity may be repeating marketing language rather than clinical understanding.
Polynucleotides represent a genuinely interesting category of aesthetic medicine. The biology is real. The early clinical results are encouraging. But the distance between "encouraging" and "established" is where your critical thinking matters most — and where a physician's willingness to be precise about uncertainty is the strongest signal of competence.
This article is written by a practicing physician for informational purposes. It is not a substitute for medical consultation. Product availability and regulatory status vary by country.
Related reading: Dermal Filler Brands: A Physician's Guide — understanding HA fillers and biostimulators alongside PN/PDRN. MCT: Skin Rejuvenation Without Heat — a mechanical approach to skin quality. Why Korea for Medical Care — context on Korea's leadership in aesthetic innovation.
Frequently Asked Questions
- What are polynucleotides and how do they differ from fillers?
- Polynucleotides are fragments of DNA, typically derived from salmon or trout sperm cells, with molecular weights usually between 50 and 1,500 kDa. Unlike hyaluronic acid fillers, which add volume mechanically, polynucleotides work biologically — they activate adenosine A2A receptors on cell surfaces, stimulate fibroblast activity, promote angiogenesis, and reduce local inflammation. The goal is tissue repair and skin quality improvement rather than volumization. They do not fill or lift; they aim to improve the biological environment of the skin.
- What is the difference between PN, PDRN, and exosomes?
- PDRN (polydeoxyribonucleotide) has a molecular weight of 50–1,500 kDa and primarily works through A2A adenosine receptor activation. PN (polynucleotide) is a broader category that includes longer-chain DNA fragments, often above 1,000 kDa, with additional mechanisms including direct scaffolding effects and ECM modulation. Exosomes are lipid-membrane vesicles secreted by cells, carrying proteins, RNA, and signaling molecules — an entirely different biological entity. All three are marketed under regenerative medicine, but their mechanisms, evidence bases, and regulatory classifications differ substantially.
- Is Rejuran the same as other polynucleotide products?
- No. Rejuran (made by Pharma Research, Korea) is a PDRN-based product derived from salmon DNA. Other products like Nucleofill (Italy) and Plinest (Italy) use polynucleotides with different molecular weight ranges, purification processes, and concentrations. Even within PDRN products, the source material, fragment size distribution, and formulation vary. Treating all PN/PDRN products as interchangeable ignores manufacturing differences that may affect clinical performance. The evidence supporting one product does not automatically transfer to another.
- What does the clinical evidence actually support for PN/PDRN?
- Randomized controlled trials support PDRN efficacy in wound healing (particularly diabetic ulcers), skin hydration improvement, and modest texture enhancement. Some controlled studies show improvement in fine lines and skin elasticity measurements. However, most aesthetic claims — dramatic wrinkle reversal, pore reduction, deep structural rejuvenation — come from uncontrolled case series, manufacturer-sponsored studies, or clinical observation rather than rigorous RCTs. The evidence is real but narrower than the marketing suggests.
- How do Korean dermatologists typically use PN/PDRN treatments?
- Korean protocols commonly involve serial intradermal injections at the papillary or upper dermal level, spaced two to four weeks apart for an initial series of three to five sessions, followed by maintenance every one to three months. Many clinics combine PN/PDRN with microneedling, laser toning, or energy-based devices in the same session or alternating sessions. The injection technique — multiple micro-deposits across the treatment area rather than bolus injection — is considered important for even distribution. Combination approaches are the norm, not the exception.